Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.40 |
| ▸ | TOP2A | P11388 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.40 |
| ▸ | PPIA | P62937 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22729543 | 0.85 | BRD4 (0.44) | BRD4TDP1L3MBTL1EPHB3TP53 | |
| SCHEMBL29839402 | 0.85 | BRD4 (0.44) | BRD4TDP1L3MBTL1EPHB3TP53 | |
| SCHEMBL22729434 | 0.74 | BRD4 (0.48) | BRD4TDP1L3MBTL1TP53POLB | |
| SCHEMBL22729676 | 0.73 | TDP1 (0.53) | BRD4TDP1L3MBTL1TP53POLB | |
| SCHEMBL22729591 | 0.73 | BRD4 (0.47) | BRD4TDP1L3MBTL1TP53POLB | |
| SCHEMBL22729727 | 0.72 | ALDH1A1 (0.32) | TDP1MAPTLMNA | |
| SCHEMBL22729512 | 0.71 | KDM4E (0.39) | BRD4L3MBTL1TP53POLBMAPT | |
| SCHEMBL3619403 | 0.70 | BRD4 (0.77) | BRD4TDP1L3MBTL1POLBMAPT | |
| SCHEMBL11549645 | 0.69 | BRD4 (0.70) | BRD4TDP1L3MBTL1TOP2ARXFP1 | |
| SCHEMBL38660185 | 0.69 | BRD4 (0.70) | BRD4TDP1L3MBTL1TOP2ARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459325-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-04 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3747885-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | BRD4 1170/4885TDP1 1609/4885L3MBTL1 1536/4885 |
| US-11459325-B2 | Heterocyclic compound | GBA1, GBA2, GALC | BRD4 1201/4885TDP1 1557/4885L3MBTL1 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.